LAUSR

FLIPI risk category progressed in 60.5% (N = 69), which was associated with inferior outcome compared with pts with stable FLIPI (39.5%, N = 45), p = 0.006 (Figure 1C). In contrast, annual FLIPI risk categories over 5 yrs in 156 observed pts who never required therapy were stable in 72 (46%), progressed in 27 (17%), were not assessed in 57 (37%). Pts with progressed versus stable FLIPI had higher risk of transformation (25.2% vs 11.3%, p < 0.001) and were treated more often initially with R‐monotherapy (38.8% vs. 19.1%, p < 0.001). Conclusions: Despite improvement in OS over the last two decades, PFS after 4th line of therapy remains less than 1 year. The data benchmarks PFS by lines of therapy, which will facilitate drug development in pts with multiply relapsed FL. The inferior outcome for pts who progress and alter their FLIPI may represent pts with adverse biology at diagnosis. We hope to identify biomarkers in this high‐risk group that would permit identification for early treatment intervention.